BPA
SLS icon

Beacon Pointe Advisors’s SELLAS Life Sciences SLS Stock Holding History

Beacon Pointe Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$37.7K – 1885
2025
Q4 		$37.7K Buy
+10,000
New +$19.4K ﹤0.01% 1487

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Beacon Pointe Advisors's SLS Position: Q1 2026 in Review

Beacon Pointe Advisors sold out of SELLAS Life Sciences (SLS) in Q1 2026, closing a stake of 10,000 shares — an estimated $37.7K sold.

Beacon Pointe Advisors first reported a position in SLS in Q4 2025 and held it in 1 quarter. The position peaked at $37.7K in Q4 2025. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Beacon Pointe Advisors reported no remaining SELLAS Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Beacon Pointe Advisors sold 10,000 SELLAS Life Sciences shares in Q1 2026, an estimated $37.7K.
  • Beacon Pointe Advisors first reported a position in SELLAS Life Sciences in Q4 2025 and held it in 1 quarter.
  • Beacon Pointe Advisors's SELLAS Life Sciences position peaked at $37.7K in Q4 2025.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.